Search Results - "Mira, José A"
-
1
Prediction of Response to Pegylated Interferon plus Ribavirin by IL28B Gene Variation in Patients Coinfected with HIV and Hepatitis C Virus
Published in Clinical infectious diseases (01-10-2010)“…Background. Variation in the IL28B gene is associated with sustained virologic response (SVR) to pegylated interferon plus ribavirin in hepatitis C virus…”
Get full text
Journal Article -
2
Liver toxicity induced by non-nucleoside reverse transcriptase inhibitors
Published in Journal of antimicrobial chemotherapy (01-03-2007)“…Liver toxicity is one of the most relevant adverse effects of antiretroviral therapy. Within the non-nucleoside reverse transcriptase inhibitors (NNRTIs),…”
Get full text
Journal Article -
3
Incidence of and Risk Factors for Symptomatic Visceral Leishmaniasis among Human Immunodeficiency Virus Type 1-Infected Patients from Spain in the Era of Highly Active Antiretroviral Therapy
Published in Journal of Clinical Microbiology (01-03-2002)“…Article Usage Stats Services JCM Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text
Journal Article -
4
Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir
Published in Journal of antimicrobial chemotherapy (01-05-2006)Get full text
Journal Article -
5
Increased Hepatocyte Fas Expression and Apoptosis in HIV and Hepatitis C Virus Coinfection
Published in The Journal of infectious diseases (01-11-2005)“…Background. Chronic hepatitis C disease (CHC) follows an accelerated course in human immunodeficiency virus (HIV) coinfection. The reasons for this are…”
Get full text
Journal Article -
6
Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus
Published in Hepatology (Baltimore, Md.) (01-10-2009)“…A few studies have assessed the observed fibrosis progression between serial liver biopsies (LB) in human immunodeficiency virus (HIV) / hepatitis C virus…”
Get full text
Journal Article -
7
Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19
Published in Journal of clinical medicine (06-09-2021)“…Background: Immunomodulatory drugs have been used in patients with severe COVID-19. The objective of this study was to evaluate the effects of two different…”
Get full text
Journal Article -
8
Benefits From Sustained Virologic Response to Pegylated Interferon Plus Ribavirin in HIV/Hepatitis C Virus—Coinfected Patients With Compensated Cirrhosis
Published in Clinical infectious diseases (01-06-2013)“…Background. The objective of this study was to determine the impact of sustained virologic response (SVR) to pegylated interferon (peg-IFN) plus ribavirin…”
Get full text
Journal Article -
9
Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort
Published in PloS one (05-02-2016)“…To assess the current frequency of ART-associated grade 3-4 transaminase elevations (TE) and grade 4 total bilirubin elevations (TBE) in HIV-infected patients…”
Get full text
Journal Article -
10
Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography
Published in European journal of gastroenterology & hepatology (01-08-2013)“…BACKGROUNDThe combination of transient elastometry with a controlled attenuation parameter (CAP) is available to evaluate hepatic steatosis (HS) along with…”
Get full text
Journal Article -
11
Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine
Published in AIDS (London) (26-03-2004)“…The hepatotoxicity of highly active antiretroviral therapy (HAART) could enhance liver fibrosis in HIV/Hepatitis C virus (HCV)-coinfected patients. Moreover,…”
Get full text
Journal Article -
12
High prevalence of hepatitis C virus infection among noninjecting drug users: association with sharing the inhalation implements of crack
Published in Liver international (01-07-2008)“…Background: Most of the prevalent cases of hepatitis C virus (HCV) infection are attributable to intravenous drug using. However, a substantial number of…”
Get full text
Journal Article -
13
Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response
Published in The Journal of infection (01-07-2013)“…Summary Objective Some experts consider that hepatitis C virus (HCV) genotype 1-infected patients harboring IL28B genotype CC should be treated with interferon…”
Get full text
Journal Article -
14
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone
Published in Journal of antimicrobial chemotherapy (01-12-2008)“…Objectives To compare the response to hepatitis C virus (HCV) therapy among human immunodeficiency virus (HIV)/HCV co-infected patients receiving a…”
Get full text
Journal Article -
15
Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin
Published in Journal of antimicrobial chemotherapy (01-10-2010)“…Objectives To evaluate the changes in liver stiffness measurement (LSM) in patients infected by hepatitis C virus (HCV) under pegylated interferon (Peg-IFN)…”
Get full text
Journal Article -
16
Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves
Published in Journal of medical virology (01-10-2013)“…Hepatitis C virus genotype 4 (HCV‐4) is highly prevalent in Spain, but the information on the molecular characterization of HCV‐4 in this region is scarce. Due…”
Get full text
Journal Article -
17
Response to Pegylated Interferon Plus Ribavirin Among HIV/Hepatitis C Virus–Coinfected Patients With Compensated Liver Cirrhosis
Published in Clinical infectious diseases (15-12-2012)“…Background. The objective of this study was to determine the efficacy of pegylated interferon (peg-IFN) plus ribavirin (RBV) in human immunodeficiency virus…”
Get full text
Journal Article -
18
Changes in the response to treatment against chronic hepatitis C between 1999 and 2015: data from a prospective cohort
Published in European journal of gastroenterology & hepatology (01-11-2016)“…BACKGROUNDThe drug options and strategies for treatment against hepatitis C virus (HCV) infection have changed considerably in the last few years. The aim of…”
Get full text
Journal Article -
19
A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers
Published in Liver international (01-04-2014)“…Background & Aims Host genetic factors could play a primary role in determining risk for cirrhosis development in HCV‐infected patients. The aims of this study…”
Get full text
Journal Article -
20
Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients
Published in Journal of antimicrobial chemotherapy (01-11-2011)“…Objectives To compare the frequency of grade 3 or 4 transaminase elevations (TEs) in HIV/hepatitis C virus (HCV) co-infected patients who started a…”
Get full text
Journal Article